



Editorial

Opioid free anaesthesia: Myth or reality?



ARTICLE INFO

Keywords:

Opioids
Anaesthesia
Pain

In this issue of *ACCPM*, P. Forget [1] proposes a qualitative study on opioid free anaesthesia (OFA). As exposed in this review, the rationale to propose OFA is based first on the question of evidence of specific activation of pain pathways under general anaesthesia and the negative consequences related to intra-operative use of opioids such as immune effects and opioid-induced hyperalgesia (OIH). Focusing on OIH, the International Association of the Study of Pain defines hyperalgesia as “Increased pain from a stimulus that normally provokes pain”. This post-operative hyperalgesia is the result of various mechanisms involving OIH, surgical trauma and related nociception. OIH is an important basic mechanism potentially involved in post-operative consequences of opioid use both in the acute phase with increased pain intensity, opioid tolerance, increased opioid use and related side effects but also in the long term with a potential exposure to chronic post-surgical pain (CPSP) [2]. OIH has been clearly identified in animal models, human volunteers [3] and patients [4]. Specific populations may be exposed to OIH. Genetic factors and pre-operative use of opioids are potential influencing factors of OIH [5]. A clinical study including 43 healthy volunteers using a painful thermal stimulus found that individuals homozygous for the met (158) polymorphism of the catechol O-methyl transferase gene had greater hyperalgesia after remifentanyl [6]. In the situation of pre-operative use of opioid to treat existing pain, this chronic administration of opioid can increase the risk of hyperalgesia [7]. In a study on the intra-operative use of ketamine in surgical patients treated before surgery with opioids, the benefit of ketamine in preventing OIH was sustained, with a morphine-sparing effect for 6 weeks after surgery [8]. The impact of perioperative opioid use on the development of opioid misuse is also an emerging problematic, which underlines the importance of a rational and limited use of opioid in surgical patients [9]. Concerning CPSP two studies have suggested that a higher dose of remifentanyl may be predictive of a higher incidence of persistent post-surgical pain after thoracotomy or cardiac surgery [10,11].

The cumulative dose of remifentanyl and the rapid withdrawal may be the predominant factors in remifentanyl-induced

hyperalgesia. The cumulative dose of remifentanyl seems the determinant factor both in experimental and clinical research [4,12]. A quantitative review confirmed the clear association between high dose remifentanyl and clinical signs of hyperalgesia [4]. However, the authors were unable to define a cut-off value responsible for this remifentanyl-induced hyperalgesia. Is there other approach to prevent opioid-induced hyperalgesia in surgical patients? Beyond opioid dose reduction, different approaches have been tested including perioperative ketamine, clonidine, propofol, non-steroidal anti-inflammatory drug, propranolol or nitrous oxide [13]. However, all these approaches can be responsible for additional side effects.

OFA is emerging as a new stimulating research perspective. The aim is to avoid the negative impact of intra-operative opioid on patient's post-operative outcomes. Reducing or eliminating opioids during general anaesthesia have been proposed for many years in the literature. OFA is based on the concept of multimodal anaesthesia. One drug will not replace opioids. It is the association of drugs and/or techniques that will allow a good quality OFA. The association can combine NMDA antagonists (ketamine, lidocaine, magnesium sulfate), sodium channel blockers [local anaesthetics (LA)], anti-inflammatory drugs (NSAID, dexamethasone, LA) and alpha-2 agonists (dexmedetomidine, clonidine). Of course, all these drugs/techniques will not be administered to the same patient. Indeed, for toxicity reasons, LA can only be administered by one route at a time (either regional anaesthesia/analgesia or IV lidocaine). For haemodynamic stability, alpha-2 agonists are the drugs of choice: IV dexmedetomidine (shorter half-life) or IV clonidine. Magnesium sulfate could also help with haemodynamic stability [14]. It is however associated with a risk of hypotension. Indeed, all these drugs administered alone have documented side effects, which have to be known and prevented by anaesthesiologists. OFA is feasible but is it associated with clinically meaningful benefits for patients? Proofs are scarce in the literature. In the past 10 years, only 10 RCTs have been published on the subject. They reported a benefit of OFA in terms of post-operative morphine sparing, Pain Scores reduction and PONV. However, these studies were usually small (from 20 to 124 patients) and the results need to be confirmed by large-scale studies. Anaesthesiologists around the world and P. Forget in his article are very enthusiastic about OFA. It is indeed exciting! However, we also need to be cautious, as a lot of questions are still unanswered. OFA cannot be formally recommended, as further proofs of its benefits are needed.

Disclosure of interest

Dominique Fletcher: consulting for Grunenthal and Biocodex
The other authors declare that they have no competing interest.

References

- [1] Forget P. Opioid-free anaesthesia. Why and how? A contextual analysis. *Anaesth Crit Care Pain Med* 2018. <http://dx.doi.org/10.1016/j.accpm.2018.05.002>.
- [2] Wilder-Smith OHG, Arendt-Nielsen L. Postoperative hyperalgesia: its clinical importance and relevance. *Anesthesiology* 2006;104:601–7.
- [3] Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanyl infusion in humans. *Anesth Analg* 1998;86:1307–11.
- [4] Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. *Br J Anaesth* 2014;112:991–1004. <http://dx.doi.org/10.1093/bja/aeu137>.
- [5] Liang D-Y, Guo T, Liao G, Kingery WS, Peltz G, Clark JD. Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence. *Pain* 2006;121:232–40. <http://dx.doi.org/10.1016/j.pain.2005.12.026>.
- [6] Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphism. *PloS One* 2009;4:e6016. <http://dx.doi.org/10.1371/journal.pone.0006016>.
- [7] Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J. Altered quantitative sensory testing outcome in subjects with opioid therapy. *Pain* 2009;143:65–70. <http://dx.doi.org/10.1016/j.pain.2009.01.022>.
- [8] Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK, et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. *Anesthesiology* 2010;113:639–46. <http://dx.doi.org/10.1097/ALN.0b013e3181e90914>.
- [9] Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. *BMJ* 2018;360:j5790. <http://dx.doi.org/10.1136/bmj.j5790>.
- [10] van Gulik L, Janssen LI, SJGM Ahlers, Bruins P, Driessen AHG, van Boven WJ, et al. Risk factors for chronic thoracic pain after cardiac surgery via sternotomy. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg* 2011;40:1309–13. <http://dx.doi.org/10.1016/j.ejcts.2011.03.039>.
- [11] Salengros J-C, Huybrechts I, Ducart A, Faraoni D, Marsala C, Barvais L, et al. Different anesthetic techniques associated with different incidences of chronic post-thoracotomy pain: low-dose remifentanyl plus presurgical epidural analgesia is preferable to high-dose remifentanyl with postsurgical epidural analgesia. *J Cardiothorac Vasc Anesth* 2010;24:608–16. <http://dx.doi.org/10.1053/j.jvca.2009.10.006>.
- [12] Cabañero D, Campillo A, Célérier E, Romero A, Puig MM. Pronociceptive effects of remifentanyl in a mouse model of postsurgical pain: effect of a second surgery. *Anesthesiology* 2009;111:1334–45. <http://dx.doi.org/10.1097/ALN.0b013e3181bfab61>.
- [13] Fletcher D, Martinez V. How can we prevent opioid induced hyperalgesia in surgical patients? *Br J Anaesth* 2016;116:447–9. <http://dx.doi.org/10.1093/bja/aew050>.
- [14] Forget P, Cata J. Stable anesthesia with alternative to opioids: are ketamine and magnesium helpful in stabilizing hemodynamics during surgery? A systematic review and meta-analyses of randomized controlled trials. *Best Pract Res Clin Anaesthesiol* 2017;31:523–31. <http://dx.doi.org/10.1016/j.bpa.2017.07.001>.

H. Harkouk^{a,b,*}, D. Fletcher^{a,b}, H. Beloeil^{c,d}

^aService d'anesthésie-réanimation, CHU de Ambroise Paré, 9, avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France

^bUnité Inserm 987, Université de Versailles Saint-Quentin en Yvelines, 55, avenue de Paris, 78000 Versailles France

^cService d'anesthésie-réanimation, CHU de Rennes, 2, rue Henri le Guilloux, 35033 Rennes, cedex 9 France

^dUnité Inserm CIC 1414, NuMeCan, université de Rennes, 2, rue du Thabor, CS 46510 35042 Rennes, cedex France

*Corresponding author at: Service d'anesthésie-réanimation, CHU de Ambroise Paré, 9, avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France

E-mail address: hakim.harkouk@aphp.fr (H. Harkouk).

Available online 18 January 2019